Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH)

PHASE4CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

November 30, 2005

Study Completion Date

January 31, 2006

Conditions
Nonalcoholic Steatohepatitis
Interventions
DRUG

Pioglitazone

30 mg/d for 8 weeks and titrated to 45 mg/d until completing 6 months of treatment.

DRUG

Placebo

Placebo is given to match pioglitazone.

Trial Locations (1)

78229

Audie L Murphy VA Hospital, San Antonio

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Takeda Pharmaceuticals North America, Inc.

INDUSTRY

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT00227110 - Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) | Biotech Hunter | Biotech Hunter